About
Branches
AstraZeneca Global Commercial | Singapore Marketing Company
Mon—Fri: 9:00 AM — 5:30 PM
Key Trials
4 trials shown
Astrazeneca
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.
- Trial number:
- NCT04642469
- Trial phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy
Astrazeneca
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor
- Trial number:
- NCT04494425
- Trial phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy
Astrazeneca
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chem
- Trial number:
- NCT04385368
- Trial phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy
Astrazeneca
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
- Trial number:
- NCT03997123
- Trial phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Chemotherapy